Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study by Haas David W, Ribaudo Heather J, Kim Richard B, Tierney Camlin, Wilkinson Grant R, Gulick Roy M, Clifford David B, Hulgan Todd, Marzolini Catia, Acosta Edward P in AIDS (London, England) (2004). PubMed

Abstract

Efavirenz is an effective antiretroviral agent, but central nervous system side effects occur commonly, and population (racial) differences in pharmacokinetics and response have been reported. Efavirenz is metabolized by cytochrome P4502B6 (CYP2B6). We investigated whether polymorphisms in CYP2B6, CYP3A4, CYP3A5, and MDR1 were associated with efavirenz central nervous system side effects and pharmacokinetics.

[ hide abstract ]

Discussed In Paper

Related In Paper

Variant Annotations

Sign in to see variant annotations.